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Abstract
Background: Activation of beta-catenin is a hallmark of hepatoblastoma (HB) and appears to play a crucial role in
its pathogenesis. While aberrant accumulation of the beta-catenin is a common event in HB, mutations or
deletions in CTNNB1 (beta-catenin gene) do not always account for the high frequency of protein expression. In
this study we have investigated alternative activation of beta-catenin by HGF/c-Met signaling in a large cohort of
98 HB patients enrolled in the SIOPEL-3 clinical trial.
Methods: We performed immunohistochemistry, using antibodies to total beta-catenin and tyrosine654-
phosphorylated beta-catenin, which is a good surrogate marker of HGF/c-Met activation. CTNNB1 mutation analysis
was also carried out on all samples. We also investigated beta-catenin pathway activation in two liver cancer cell
lines, HuH-6 and HuH-7.
Results: Aberrant beta-catenin expression was seen in the cytoplasm and/or nucleus of 87% of tumour samples.
Our results also revealed a large subset of HB, 83%, with cytoplasmic expression of tyrosine654-phosphorylated
beta-catenin and 30% showing additional nuclear accumulation. Sequence analysis revealed mutations in 15% of
our cohort. Statistical analysis showed an association between nuclear expression of c-Met-activated beta-catenin
and wild type CTNNB1 (P-value = 0.015). Analysis of total beta-catenin and Y654-beta-catenin in response to HGF
activation in the cell lines, mirrors that observed in our HB tumour cohort.
Results: We identified a significant subset of hepatoblastoma patients for whom targeting of the c-Met pathway
may be a treatment option and also demonstrate distinct mechanisms of beta-catenin activation in HB.
Introduction
Hepatoblastoma is a rare malignant tumor of the liver
that occurs in young infants with a median age at diag-
nosis of 16 months [1]. Hepatoblastoma accounts for 1%
of new cancer diagnoses in childhood and is the most
common childhood liver cancer [2]. While most cases of
hepatoblastoma (HB) are sporadic and its aetiology is
unknown, there is a close association of HB with devel-
opmental syndromes such as the Beckwith-Wiedemann
Syndrome (BWS) and Familial Adenomatous Polyposis
(FAP) [3,4].
Several distinct histological subtypes of hepatoblas-
toma exist. These include wholly epithelial tumours,
with pure fetal and mixed fetal/embryonal histology;
tumours with mixed epithelial and mesenchmyal fea-
tures; and several types of transitional, small and large
cell undifferentiated tumours [5]. This heterogeneous
tumour spectrum appears to reflect distinct patterns of
hepatic embryogenesis, indicating a developmental ori-
gin for HB, and such tumour heterogeneity may account
for their variation in clinical behaviour [6].
Of several distinct developmentally regulated pathways
known to be active in hepatoblastoma, such as IGF2/
H19 [7,8], Notch [9], and Wnt/b-catenin [9,10], it is the
Wnt/b-catenin pathway that is most closely implicated
in its origin [9-15]. A common immunohistochemical
finding in HB is the aberrant accumulation of b-catenin
protein in the cytoplasm or nucleus [11,12,16]. Several
previous studies of sporadic HB have identified muta-
tions or deletions clustered in exon 3 of CTNNB1,t h e
gene for b-catenin [11-13,15,17-19].
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phorylated at specific N-terminal serine and threonine
residues by the APC/Axin/GSK3b protein complex
resulting in its ubiquitination and subsequent degrada-
tion, thus maintaining tight control of b-catenin levels
within normal cells [20]. Wnt ligand binding inhibits ser-
ine/threonine phosphorylation of b-catenin, leading to its
cytoplasmic accumulation. Hypophosphorylated b-cate-
nin binds TCF/LEF transcription factors, translocates to
the nucleus and activates the expression of many target
genes, including those involved in cell proliferation (e.g.
c-myc and cyclin D1), anti-apoptosis (e.g. survivin), inva-
sion (e.g. matrix metalloproteinases) and angiogenesis (e.
g. VEGF) [20,21]. The vast majority of missense muta-
tions reported in a variety of human cancers (2381/2394)
are within the small GSK3b-binding region of exon 3 of
the CTNNB1 gene examined in our study (http://www.
sanger.ac.uk/genetics/CGP/cosmic) and result in aberrant
accumulation of b-catenin in the cell.
Canonical Wnt/b-catenin signaling directly alters gene
expression and is a key regulator of cell proliferation,
differentiation, and apoptosis during normal liver devel-
opment, so mutation or deletion within the b-catenin
gene suggests a crucial role of this pathway in the ori-
gins of embryonal liver tumors [22,23](13-15). When
stabilized by mutation or deletion in CTNNB1, b-cate-
nin causes pathological gene activation and promotes
hepatocyte proliferation [24].
However, a disparity exists, because the very high fre-
quency of aberrant b-catenin protein accumulation seen
in these tumors cannot be accounted for by mutation or
deletion in the CTNNB1 gene alone [25]. While direct
activation of b-catenin by CTNNB1 mutation is com-
mon in many tumours, pathologic activation of b-cate-
nin by HGF/c-Met signaling with associated
transformation has also been reported in several tumors
and its activation has been previously reported in hepa-
toblastoma [26]. This Wnt-independent activation of b-
catenin was identified involving a separate pool of b-
catenin located at the inner surface of the cell mem-
brane in association with c-Met [27].
c-Met is the tyrosine kinase receptor for hepatocyte
growth factor (HGF), that upon ligand binding under-
goes tyrosine autophosphorylation and in turn triggers
the activation of several pathways controlling epithelial-
mesenchymal morphogenesis, angiogenesis and cell-cell
adhesion [28]. In the liver, the HGF/c-Met pathway has
a crucial role the activation of liver cell regeneration fol-
lowing injury or partial hepatectomy, and a similar
response is seen following kidney and heart injury sug-
gesting a general role promoting tissue regeneration and
repair [29]. Elevated serum levels of HGF have pre-
viously been reported in children following resection of
hepatoblastoma [30,31].
Upon signaling by HGF, c-Met becomes phosphory-
lated at tyrosine residues Y1234 and Y1235 and in turn
tyrosine phosphorylates b-catenin at residues Y654 and
Y670, causing its dissociation from c-Met at the cell
membrane. Tyrosine phosphorylated b-catenin is pro-
tected from serine/threonine phosphorylation and subse-
quent proteosomal degradation allowing its
accumulation in the nucleus where it acts as a TCF/LEF
transcription cofactor. Thus, HGF/c-Met related activa-
tion of b-catenin occurs independent of the canonical
Wnt/b-catenin pathway [21,27,32].
Under the auspices of the International Society of Pae-
diatric Oncology Liver Tumour strategy group (SIOPEL)
we have investigated the status of b-catenin activation in
tumours from patients prospectively enrolled in the
SIOPEL 3 hepatoblastoma clinical trial [33]. Here we
report an analysis of the role of HGF/c-Met related b-
catenin activation and CTNNB1 mutation activation of
b-catenin in a large cohort of 84 patients with hepato-
blastoma. This characterisation of b-catenin activation
by the c-Met pathway may have clinical relevance
because several HGF/c-Met small molecule inhibitors
are now in early phase clinical trials.
Materials and methods
Patients and SIOPEL HB clinical trials
SIOPEL Liver tumor clinical trials are international, pro-
spective, clinical trials run under the auspices of the
SIOP Liver Tumor Strategy Group (SIOPEL). Our
cohort comprises patients prospectively enrolled into
the SIOPEL 3 clinical trial, a randomised study which
opened in March 1998, designed to evaluate the effec-
tiveness of preoperative chemotherapy for standard risk
(SR) HB with either cisplatin (CDDP) alone or in com-
bination with doxorubicin (PLADO). A detailed descrip-
tion of the SR patient cohort, its clinical features,
staging and outcome has previously been reported [33].
SIOPEL 3 patients with high risk (HR) HB were all trea-
ted preoperatively with SUPERPLADO, a three-drug
combination of Cisplatin, Doxorubicin and Carboplatin
and the results have been reported [34]. All patients
were recruited to the SIOPEL 3 clinical trial with appro-
priate informed consent. This specific study was
reviewed and approved by the New Zealand Health
Research Council Multi-regional ethics committee
(MREC).
Tumor samples
In this study we have accessed a representative cohort of
84 HB patients with clinical, histologic and survival data
available for most samples. Both diagnostic and post-
chemotherapy samples were available for fourteen
patients bringing the total number of samples analysed
to 98. In the case of diagnostic samples there was
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(FFPE) tumor block available containing the entire
biopsy material on which the diagnosis was made. For
each post-chemotherapy case, the most representative
FFPE block was identified by examination of slides
stained with haematoxylin and eosin (H+E). From the H
+E slides, representative tumor and adjacent normal tis-
sue areas were selected by a pathologist (C.M.) for sub-
sequent tissue array construction.
Tissue Array Construction
A tissue microarray (TMA) was constructed by deposit-
ing a 1 mm core of each tumor or normal tissue into a
wax recipient block using the Manual Tissue Arrayer I
(Beecher Instruments Inc., Sun Prairie, WI, USA). In
cases where tumor heterogeneity was evident, different
representative areas of the tumor were sampled for
TMA construction. The tissue array block was made in
duplicate and 4 μms e c t i o n so ft h eT M Ab l o c k sw e r e
cut for subsequent use in immunohistochemical (IHC)
analysis. One TMA section was also stained with H+E
for evaluation by pathologists (CM +CT).
Histologic features of the HB samples
The sample cohort consists of 98 samples from 84
patients comprising 62 diagnostic tumour biopsies and
36 post-surgical specimens (both diagnostic and surgical
specimens available in 14 cases). Histologic information
was available for 91 samples. The tumours were exam-
ined centrally and classified as either wholly epithelial (n
= 33) or mixed epithelial and mesenchymal (n = 54).
One tumour was diagnosed as hepatocellular carcinoma
(fibrolamellar type) and one as a small cell undifferen-
tiated (SCUD). The epithelial component was further
subtyped as pure fetal (n = 43), embryonal (n = 3) or
mixed fetal and embryonal (n = 41). Two tumors were
subtyped as macrotrabecular type. Focal anaplasia was
seen in three tumors and cholangioblastic features in
two tumors. Thirteen cases of osteoid formation were
noted in the histology reports with additional osteoid
formation in a post-chemotherapy sample that lacked
osteoid in the diagnostic biopsy. Teratoid features were
noted in seven samples.
Clinical characteristics of patients for survival analysis
Clinical information that classified patients into the two
well-defined risk groups was available for 71 patients in
our cohort. Twenty-seven of t h e s ew e r eh i g h - r i s ka n d
forty-four were standard risk. Of these 71 patients, nine
were born with low birth weight. PRETEXT classifica-
tion revealed that there were two PRETEXT stage 1
patients, twenty-two stage 2, thirty-one stage 3 and six-
teen stage 4 patients. Only two patients had serum AFP
levels of < 100 at diagnosis, making them high-risk.
Eight and seven patients had portal vein and vena cava
involvement respectively, and extrahepatic intra-abdom-
inal disease was seen in three patients also making them
high-risk cases. Metastatic disease was present at diag-
nosis in thirteen children. Relapse or progression in five
HR cases resulted in the death of four patients. In the
standard-risk group there were six relapses leading to a
single death from disease.
Immunohistochemistry
Briefly, 4 μm TMA slides were deparaffinized with
xylene and ethanol. Antigen retrieval was performed by
pressure cooking for 2 minutes in citrate buffer pH6.0.
Endogenous peroxidases were blocked with 0.3% hydro-
gen peroxide and non-specific binding was blocked with
normal goat serum. Slides were incubated overnight at
4°C with primary antibodies: Y1234/5-c-Met at 1:300
dilution, Y654-b-catenin at 1:25 dilution and b-catenin
at 1:200 (All from Abcam, Cambridge, UK). The EnVi-
sion HRP/DAB detection system (Dako, Glostrup, Den-
mark) was used to visualise the results. Slides were
lightly counterstained with haematoxylin. All antibodies
were optimized for use in IHC using breast tumour con-
trol tissue and the appropriate positive and negative
controls were used.
Evaluation of Immunostaining
Immunostaining for b-catenin was scored as normal
membranous, diffuse or focal cytoplasmic and diffuse or
focal nuclear staining. Staining for Y654-b-catenin was
scored as negative, cytoplasmic and/or nuclear staining.
Staining for Y1234/5-c-Met was scored as positive (cyto-
plasmic) or negative. Each array duplicate was also
stained and the results collated. The staining intensity
was noted but not factored, as differing age of donor
blocks and variation in fixation methods can impact on
staining intensity. The IHC results were analysed in
conjunction with two pathologists (CM and CT).
RNA extraction from tumour and normal tissue
Representative areas of tumour were identified on H+E
slides by pathologists and a 1 mm tissue core removed
from corresponding areas on paraffin blocks. The RNA
was extracted using RecoverALL™ Total Nucleic Acid
Isolation kit (Ambion, Austin TX, USA) as per manufac-
turer’s instructions. Normal adjacent tissue was also
removed and RNA extracted where it was available in
62 cases.
CTNNB1 mutation detection
Samples with the following quality parameters were ana-
lysed for CTNNB1 gene mutations: Optical density ratio
260/280 of 1.8 - 2.2 and RNA concentration of > 20 ng/
ul using a Nanodrop spectrometer (Thermo Scientific,
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gene was amplified that includes the b-catenin regulatory
region of exon 3 (codons 32-45) using the following pri-
m e rp a i r( B - C a t 3 / B - C a t 2 ) :5 ’ GATTTGATGGAGTTG-
GACATGG 3’ and 5’ TCTTCCTCAGGATTGCCTT 3’.
Samples were reverse transcribed and amplified using
One-Step RT-PCR kit (QIAGEN, Dusseldorf, Germany)
on a DNA Engine Thermal Cyclar (BioRad, Hercules,
CA, USA). Reverse transcription was at 50°C for 30 min-
utes followed by first strand synthesis at 95°C for 15 min-
utes. 35 cycles of 30 seconds each of denaturation at 94°
C, annealing at 52°C and extension at 72°C were carried
out. Each reaction contained 1 μl RNA template, 2 μlo f
enzyme mix, 0.6 mMol of forward and reverse primers,
400 μM of each dNTP, 2.5 mM MgCl2 in a final reaction
volume of 50 μl. RT-PCR products were visualised on a
1.5% agarose gel with ethidium bromide. Amplified RT-
PCR products were purified using QIAquick PCR purifi-
cation kit (QIAGEN) as per manufacturer’si n s t r u c t i o n s .
Cycle sequencing was carried out on a GeneAmp
® PCR
System 9700 thermocycler using ABI Prism Dye Termi-
nator Cycle Sequencing Ready Reaction Kit (Applied Bio-
systems, Foster City, CA, USA) using 20 ng RT-PCR
product. Sequencing products were run on an ABI 373A
sequencer (Applied Biosystems) and all mutations were
verified by sequencing the sense and anti-sense strands.
Mutation analysis was carried out using Variant™ Repor-
ter Software (Applied Biosystems) and showed good
quality traces spanning the region of interest.
Tissue Culture
Human hepatoblastoma cells, Huh-6 (JCRB, Osaka,
Japan) were routinely maintained in minimum essential
media (MEM) containing 10% FBS and penicillin/strep-
tomycin. The human hepatocellular carcinoma cell line
Huh-7 (JCRB) was cultured in Dulbecco’s minimum
essential media (D-MEM) with 10% FBS and penicillin/
streptomycin. The cells were serum starved for 24 hours
prior to treatment with recombinant human HGF (Invi-
trogen, Carlsbad, CA, USA) to a concentration of 50 ng/
ml for 30, 60, 90 and 120 minutes.
Preparation of Nuclear and Cytoplasmic proteins extracts
Nuclear and cytoplasmic protein fractions were isolated
from the cell lines at the timepoints indicated with the
CelLytic™ NuCLEAR™ Extraction kit (Sigma
®,M i s -
souri, USA). The lysate protein concentrations were
determined by bicinchoninic acid protein assay using
BSA as a standard (Pierce, Rockford, IL, USA). Aliquots
of the samples were stored at -80°C until use.
RNA extraction from cell lines
Total RNA was extracted from the HuH-6 and Huh-7
cell lines using the PARIS™ Protein and RNA Isolation
kit (Ambion) and CTNNB1 mutation detection was car-
ried out as outlined above for the two cell lines.
Gel Electrophoresis and Western Blotting
Approximately 20 μg of protein sample were run on
NuPAGE 4-12% BisTris gels (Invitrogen) with MES-SDS
buffer (Invitrogen) using the Xcell SureLock™ Mini-Cell
(Invitrogen). The protein marker used was Precision Plus
Protein™ Standards (BioRad). The iBlot Gel Transfer
Device (Invitrogen) was used for western blotting of pro-
teins. The filters were probed with anti-Y654 b-catenin
(Abcam, 1:150) and anti-b-catenin (Abcam, 1:1000). The
filters were stripped with a mild stripping buffer contain-
ing 1.5% glycine, 0.1% SDS and reprobed after each blot.
The immunoblots were incubated for 1 hour with the
appropriate secondary antibodies coupled to horseradish
peroxidase followed by exposure to ECL plus chemilumi-
nescence reagents (GE Healthcare Biosciences, Piscat-
away, NJ, USA) and autoradiography. Immunoblotting
with anti-TBP for nuclear proteins and anti-b-actin for
cytoplasmic extract was used to confirm equal loading.
Statistical Analysis
Results were analysed with StatView software (Abacus
Concepts Inc., USA). Statistical comparisons were made
using Pearson’s Chi-squared test with Yates’ continuity
correction data. A P-value of < 0.05 was considered sta-
tistically significant.
Results
Aberrant b-catenin expression in hepatoblastoma
We examined total b-catenin protein expression on a HB
tissue array using IHC. A total of 87% (85/98) of tumours
in our clinical cohort showed aberrant expression of b-
catenin in the nucleus and cytoplasm (38/98) or in the
cytoplasm alone (47/98) (Figure 1a and 1b). Normal
membranous staining alone was observed in seven cases
and the remaining six tumours were completely negative
for total b-catenin staining. Samples of adjacent normal
tissue had a normal membranous b-catenin staining pat-
tern in 46/48 cases available for examination (Figure 1c).
The remaining two normal samples showed focal cyto-
plasmic staining. These results are similar to those pub-
lished previously in HB studies [18,35,36]. However the
frequency of mutations in the CTNNB1 gene varies
widely in studies of HB, from 13% to 70% [19,37]. To
determine whether aberrant b-catenin protein expression
is a result of gene mutation, we identified the frequency
and type of CTNNB1 mutations in our cohort.
CTNNB1 mutation analysis of hepatoblastomas from
SIOPEL clinical trial
To identify CTNNB1 mutations we extracted total RNA
from corresponding tissue cores of hepatoblastoma. A
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3 of the CTNNB1 gene (codons 32-45) was amplified suc-
cessfully by RT-PCR in 92 of the samples. Lack of ampli-
fication in 6 samples may be due to deletion of exon 3 of
CTNNB1. We attempted to amplify a region spanning
exon 2 to exon 4 in these 6 samples but were unsuccess-
ful. Therefore our estimation of samples containing dele-
tions may be inaccurate. We identified 11 different point
mutations in 14 of 98 samples (15%) (Table 1). These are
all missense mutations affecting phosphorylation sites in
the regulatory region of the gene and have been pre-
viously reported [17,38]. The mutations found, resulted
in the following changes at the protein level; 32D > N,
32D > Y, 32D > V, 32D > A, 33S > P, 33S > C, 34G > R,
34G > E, 34G > V, 35I > P, 35I > S, 37S > Y. One HB
patient (CCRG 64) showed the same sequence variation
(missense 32D > V) in both diagnostic and post che-
motherapy tumour samples. RNA from adjacent normal
tissue was also analysed from 62 cases including nine
tumours that harboured mutations. All of these samples
displayed wild type CTNNB1 showing that the mutations
found were somatic variants (results not shown). The fre-
quency of CTNNB1 mutations (14/98) and possible dele-
tions (6/98) in our cohort was significantly lower than
the frequency of aberrant expression of b-catenin protein
and statistical analysis shows no correlation between
aberrant b-catenin accumulation and gene mutation/
deletion. This prompted us to investigate alternative
pathways of b-catenin activation in hepatoblastomas in
our patient cohort.
Figure 1 Immunohistochemical staining of HB using an antibody to b-catenin. (a) Cytoplasmic staining of b-catenin in hepatoblastoma. (b)
Nuclear and cytoplasmic accumulation of b-catenin in hepatoblastoma. (c) Normal staining of the liver cell membrane using an antibody to b-
catenin.
Table 1 Histologic type and subtype, b-catenin and Y654 b-catenin IHC and CTNNB1 gene status of hepatoblastomas
with mutations.
Case Number Histologic Type Histologic Subtype b-catenin Y654-b-catenin CTNNB1 mutation
CCRG9 Epithelial Pure fetal dc cytoplasmic 32D > Y
CCRG15 Epithelial Fetal/embryonal dn negative 33S > C
CCRG16 Mixed Fetal/embryonal dc+dn cytoplasmic 32D > Y
CCRG48 Epithelial Pure fetal dc cytoplasmic 37S > Y
CCRG61 Epithelial Pure fetal dc cytoplasmic 34G > V
CCRG63 Epithelial Fetal/embryonal dn nuclear 32D > N
CCRG64
a Epithelial Fetal/embryonal dc+fn negative 32D > V
CCRG64
b Epithelial Pure fetal fn negative 32D > V
CCRG65 Epithelial Pure fetal dn negative 34G > R
CCRG68 Mixed Fetal/embryonal dc cytoplasmic 34G > E
CCRG70 Epithelial Pure fetal dc+fn cytoplasmic 32D > V
CCRG79 Epithelial Fetal/embryonal dc+fn cytoplasmic 32D > N
CCRG82 Mixed Pure fetal fc+fn cytoplasmic 33S > P
CCRG87 Mixed Pure fetal dc+dn cytoplasmic 35I > S
CCRG88 Mixed Fetal/embryonal dc+dn cytoplasmic 32D > V
a Diagnostic specimen from sample CCRG64.
b Post-chemotherapy specimen from sample CCRG64. Abbreviations: dc, diffuse cytoplasmic; dn, diffuse nuclear; fc,
focal cytoplasmic; fn, focal nuclear
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catenin in HB
To investigate the possibility of Wnt-independent acti-
vation of b-catenin, we analysed our tumour cohort for
possible HGF/c-Met related tyrosine phosphorylation of
b-catenin. We stained the hepatoblastoma tissue array
using an antibody recognising tyrosine 654-phosphory-
lated b-catenin (Y654-b-catenin). This identified positive
staining in the cytoplasm of 82/98 (83%) tumours with
an additional 27 (28%) showing nuclear accumulation of
Y654-b-catenin. In 78 hepatoblastoma with wild type
CTNNB1, 26 (33%) showed nuclear expression of Y654-
b-catenin, 44 (56%) showed cytoplasmic staining with
only 7 (9%) negative for staining. In contrast, IHC analy-
s i so f2 0h e p a t o b l a s t o m aw i t hCTNNB1 mutations or
possible deletions showed 5 (25%) were completely
negative for Y654-b-catenin (Figure 2a), 14 (70%) had
cytoplasmic staining alone (Figure 2b), and only one of
20 (5%) had nuclear expression in addition to cytoplas-
mic staining (Figure 2c).
Statistical analysis shows a significant correlation
between nuclear accumulation of tyrosine-phosphory-
lated b-catenin and HB tumours with wild-type
CTNNB1 (P-value = 0.015).
To verify that tyrosine phosphorylation of b-catenin is
specifically due to activation of the HGF/c-Met pathway
we examined the expression of tyrosine 1234 and 1235-
phosphorylated c-Met. These tyrosine residues become
auto-phosphorylated specifically in response to HGF
ligand binding. Eighty-one tumour samples (82%) were
positive for Y1234/5-c-Met staining (Figure 3a) and the
remaining 17 samples were negative (Figure 3b). A sin-
gle tumour sample showed a distinct nuclear staining
pattern with the antibody to Y1234/5-c-Met (Figure 3c).
Statistical analysis showed a 70% correlation between
Y1234/5-c-Met and Y654-b-catenin expression (r = 0.7).
No correlations between staining patterns and histologic
subtypes were found with any of the antibodies used.
Cell line expression of total b-catenin and Y654-b-catenin
in response to HGF activation mirrors that of HB tumours
To corroborate our immunohistochemistry findings on
tissue array, we analysed in vitro total b-catenin and
Y654-b- c a t e n i np r o t e i ne x p r e s s i o ni nr e s p o n s et oe x p o -
sure to HGF in two liver tumour cell lines, one with
a n do n ew i t h o u tm u t a t i o ni nCTNNB1 (Huh-6 and
Huh-7 respectively). To determine their CTNNB1 status,
the Huh-6 and Huh-7 cell lines were analysed for
CTNNB1 mutations in exon 3 using RT-PCR and
sequencing as outlined above. The hepatoblastoma cell
line, Huh-6, carried a missense mutation of G34G > V,
ak n o w nv a r i a n to fCTNNB1 while the hepatocellular
carcinoma cell line, Huh-7, was wild type CTNNB1 (Fig-
ure 4).
These cell lines were then routinely cultured and
serum starved for 24 hours prior to treatment with HGF
at various timepoints. Total b-catenin expression was
assessed by immunoblot of the nuclear and cytoplasmic
fractions. As expected the Huh-6 cell line bearing a
CTNNB1 mutation expressed b-catenin in both nucleus
and cytoplasm even in untreated cells (T0) cells due its
activating mutation. On exposure to HGF, nuclear and
cytoplasmic levels of total b-catenin increased through
each timepoint peaking at 90 minutes (Results not
shown). In contrast, total b-catenin in the wild type
Huh-7 cell line was almost undetectable in the nuclei,
and the level seen in the cytoplasm is noticeably lower
than that of HuH-6 cells. Upon exposure to HGF, total
b-catenin increased in the cytoplasm and was also
detected in the nuclei of HuH-7 cells.
Figure 2 Immunohistochemical staining of HB using an antibody to Y654-b-catenin. (a) Hepatoblastoma negative for staining with an
antibody to Y654- b-catenin. (b) Diffuse cytoplasmic staining of Y654- b-catenin. (c) Nuclear and cytoplasmic staining of Y654- b-catenin in
hepatoblastoma.
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allowed us to determine how much of the observed
nuclear b-catenin expression may be due to activation
by HGF/c-Met rather than an activating CTNNB1 muta-
tion. No Y654-b-catenin was seen in any untreated cell
fraction, in either the wild type or mutant cell lines.
However, upon treatment with HGF the wild type Huh-
7 cell line showed significantly more b-catenin expres-
sion in the nuclei and cytoplasm compared to Huh-6
(Figure 5).
Discussion
The accumulation of b-catenin appears to be a crucial
event in the tumorigenesis of hepatoblastoma. And
although b-catenin gene mutations have been widely
reported in hepatoblastoma, a disparity exists between
the reported frequency of aberrant b-catenin protein
accumulation and mutations in the CTNNB1 gene
(Table 2).
Aberrations in the CTNNB1 gene have been reported
in up to 75% of HB, with mutation frequencies ranging
from 13 - 33% and deletions frequencies of 0 - 51%
[12,13,18,19,38]. Our study, in common with several
others, has shown a lower frequency of mutations (14%)
but a high level of b-catenin protein accumulation (87%)
in our sample group [25,36,37]. No deletions in exon 3
of CTNNB1 were detected in our sample group, but this
m a yb ea nu n d e r - e s t i m a t i o na sw ew e r eu n a b l et o
amplify the gene fragment in 6% of our tumours. The
lack of amplification in these samples may be due to
RNA fragmentation caused by the formalin-fixation pro-
cess or may have a true deletion. To err on the side of
caution we designated these samples as having possible
deletions. Our results serve to corroborate previous stu-
dies of b-catenin activation in the pathogenesis of HB in
the largest cohort studied to date but the discrepancy in
mutation frequencies implies that an alternative activa-
tion of b-catenin may occur.
Danilkovitch-Miagkova et al showed that c-Met tyro-
sine phosphorylation of
®-catenin has the same effect
(same oncogenic transcription) as activation of
®-catenin
through the Wnt pathway and further studies have
implicated c-Met activation of
®-catenin in cancer
pathogenesis [29,32,39]. More recently, Cieply et al
investigated hepatocellular (HCC) tumour characteristics
occurring in the presence or absence of mutations in
CTNNB1. The authors found that the fibrolamellar (FL)
tumours had the highest tyrosine-654-phosphorylated-
®-catenin (Y654-
®-catenin) levels in the study and these
Figure 3 Immunohistochemical staining of HB using an antibody to Y1234/5-c-Met. (a) Hepatoblastoma positive for staining with an
antibody to Y1234/5-c-Met. (b) Negative staining of Y1234/5-c-Met. (c) Nuclear staining of Y1234/5-c-Met seen in a single case of
hepatoblastoma.
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Figure 4 Direct sequence analysis of exon 3 of b-catenin in
HuH-7 and HuH-6 cell lines. HuH-6 carries a G T transversion,
resulting in a glycine to valine amino acid change in codon 34.
HuH-7 displays wildtype b-catenin.
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[40].
This prompted us to analyse our samples for c-Met
related
®-catenin protein activation. We used an antibo-
dies to detect tyrosine-654 phosphorylated
®-catenin
(Y654-
®-catenin) and tyrosine-1234 and 1235-c-Met
(Y1234/5-c-Met) as surrogate markers for HGF/c-Met
activation. Using this method we found that a large pro-
portion of our cohort (79%) showed c-Met related
®-catenin protein activation. Statistical analysis of
tumour groups with and without mutations shows a sig-
nificant correlation between wild type b-catenin and
nuclear accumulation of Y654-b-catenin. This is in
keeping with the findings of Cieply et al in hepatocellu-
lar carcinoma. To validate our tumour findings, we
looked at the effects of HGF treatment on b-catenin
and Y654-b-catenin in two liver cancer cell lines, with
and without CTNNB1 mutations. The results reflected
those seen in HB tumours with c-Met activated b-cate-
nin found only in the cell line with wild type CTNNB1
following HGF treatment. It must be noted, however,
that nuclear Y654 b-catenin was seen in two tumours
carrying mutations/deletions so an overlap of activation
pathways may occur. Furthermore thirteen tumours
harbouring mutations/deletions also showed Y654 b-
catenin expression in the cytoplasm. Further studies
must be carried out to ascertain the effect of mutated b-
catenin on the nuclear accumulation of the c-Met
related b-catenin pool.
Overall analysis of tumours with aberrant b-catenin
expression revealed only a small percentage (5%) that
has neither mutations in the CTNNB1 gene nor expres-
sion of tyrosine654-phosphorylated b-catenin (Figure 6).
These tumours may have mutations in other genes such
as AXIN or APC that lead to abnormal b-catenin accu-
mulation or activation through a different pathway.
These findings underline that aberrant activation of b-
catenin may be critical to the pathogenesis of HB but
the means of this activation may not be as important as
was previously thought.
Our finding of a large number of tumours (79%) with
c-Met activated b-catenin may be relevant to treatment
of HB. Although treatment with cisplatin or PLADO fol-
lowed by resection is highly successful there remains >
1 5 %o fH Bt h a ts u f f e rf r o mr e l a p s e .T h e s er e l a p s e
patients are often refractive to conventional chemother-
apy and have a survival rate of < 20%. The translation of
our findings may be important for design of future
Table 2 Review of previous b-catenin studies in hepatoblastoma
Sample number Mutation frequency Deletion frequency Protein accumulation References
21 19% 0% 67% Curia et al 2008 [36]
17 24% 35% 100% Yamaoka et al 2006 [14]
27 33% 37% - Taniguchi et al 2002 [15]
16 31% 44% - Udatsu et al 2001 [19]
68 16% 51% 100% Takayasu et al 2001 [18]
30 13% 0% 97% Park et al 2001 [37]
18 33% 34% 100% Wei et al 2000 [13]
52 25% 15% - Koch et al 1999 [12]
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Figure 5 Immunoblotting of nuclear and cytoplasmic fractions extracted from HuH-6 and HuH-7 cell lines before and after HGF
treatment. Antibodies to b-catenin and Y654- b-catenin were used to probe the blots. Anti-TBP and anti- b-actin were used to ensure equal
loading.
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therapy, allowing for fewer side effects or inclusion of c-
Met inhibitors in salvage therapy following relapse.
Our findings may also have an application in the
treatment of other tumours that display
®-catenin acti-
vation without associated gene mutation. Somatic muta-
t i o n si ne x o n3o ft h e
®-catenin gene have been
reported in a variety of cancers (16, 32). However, aber-
rant accumulation of
®-catenin without activating muta-
tions has been reported in cancers such as
gastrointestinal carcinoid tumour, ovarian cancer, cuta-
neous lymphoma, malignant melanoma and pancreatic
adenocarcinoma [41-46]. HGF/c-Met activation of
®-catenin may account for the discrepancies between
gene mutation and protein expression seen in these
tumours and this could indicate susceptibility to RTK-
targeting agents in the treatment regimen.
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